良性前列腺增生手术治疗相关的商业保险与患者自付费用评估
基于OptumLabs数据仓库2015至2021年25,407例接受良性前列腺增生手术的商业保险男性,比较六种术式的总医疗费用。水蒸气热疗指数手术费用最低(2637美元),简单前列腺切除术最高(14,423美元);合并5年随访费用中钬激光剜除术最低(31,926美元),前列腺尿道提升术最高(36,596美元)。
要点
- 水蒸气热疗指数手术总费用最低(2637美元),简单前列腺切除术最高(14,423美元)。
- 合并指数手术与5年随访费用,钬激光剜除术最低(31,926美元),前列腺尿道提升术最高(36,596美元)。
- 微创选项如水泵蒸气热疗可能提供初始费用降低,但钬激光剜除术和简单前列腺切除术随访费用更低。
核心结论
- 良性前列腺增生手术治疗与显著的系统层面医疗费用相关,不同术式影响程度不同。
- 微创选项如水蒸气热疗可能提供初始费用降低,但钬激光剜除术和简单前列腺切除术与更低的随访费用相关。
研究设计与样本
- 利用OptumLabs数据仓库识别2015至2021年间接受目标手术(简单前列腺切除术、经尿道前列腺电切术、钬激光剜除术、前列腺光汽化术、前列腺尿道提升术或水蒸气热疗)的商业保险良性前列腺增生男性。
- 共纳入25,407例患者,采用广义线性模型在控制人口学和临床特征后估算调整后费用。
- 水蒸气热疗组因数据有限被排除在扩展随访分析之外。
主要发现
- 共25,407例患者中,10,117例(40%)接受经尿道前列腺电切术,6,353例(25%)接受前列腺尿道提升术,5,411例(21%)接受前列腺光汽化术,1,319例(5%)接受简单前列腺切除术,1,243例(5%)接受水蒸气热疗,964例(4%)接受钬激光剜除术。
- 指数手术总医疗费用:水蒸气热疗最低为2,637美元(95%CI:2,513-2,761美元),简单前列腺切除术最高为14,423美元(95%CI:12,772-16,075美元)。
- 合并指数手术与5年随访总医疗费用:钬激光剜除术最低为31,926美元(95%CI:29,704-34,148美元),前列腺尿道提升术最高为36,596美元(95%CI:35,369-37,823美元)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 水蒸气热疗组因数据有限被排除在扩展随访分析之外。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate and compare the financial burden of various surgical interventions for the management of benign prostatic hyperplasia (BPH). METHODS: We identified commercially insured men with a diagnosis of BPH who underwent a procedure of interest (simple prostatectomy (SP), transurethral resection of the prostate (TURP), holmium laser enucleation of the prostate (HoLEP), photovaporization of the prostate (PVP), prostatic urethral lift (PUL), or water vapor thermal therapy (WVTT)) between 2015 and 2021 with the OptumLabs Data Warehouse. Primary outcome was total health care costs (THC) which included both patient out-of-pocket (OOP) and health plan paid costs for the index procedure and combined follow-up years 1-5. A generalized linear model was used to estimate adjusted costs controlling for demographic and clinical characteristics. Patients undergoing WVTT were excluded from extended follow-up analyses due to limited data. RESULTS: Among 25,407 patients with BPH, 10,117 (40%) underwent TURP, 6353 (25%) underwent PUL, 5411 (21%) underwent PVP, 1319 (5%) underwent SP, 1243 (5%) underwent WVTT, and 964 (4%) underwent HoLEP. Index procedure costs varied significantly with WVTT being the least costly [THC: $2637 (95% confidence interval (CI): $2513-$2761)], and SP being the costliest [THC: $14,423 (95% CI: $12,772-$16,075)]. For aggregate index and 5-year follow-up costs, HoLEP ($31,926 [95% CI: $29,704-$34,148]) was the least costly and PUL ($36,596 [95% CI: $35,369-37,823]) was the costliest. CONCLUSION: BPH surgical treatment is associated with significant system-level health care costs. The level of impact varies between procedures. Minimally invasive options, such as WVTT, may offer initial cost reductions; however, HoLEP and SP are associated with lower follow-up costs.
引用
- Wymer KM, Thao V, Narang G, et al. Evaluation of Private Payer and Patient Out-of-Pocket Costs Associated With the Surgical Management of Benign Prostatic Hyperplasia. Urology. 2023. PMID: 38065310. doi:10.1016/j.urology.2023.10.038
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。